1-amino-triazolo(1,5-A)pyridine-substituted urea derivative and uses thereof
Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof, and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof, that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
1. A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I),
or a pharmaceutically acceptable salt or a crystalline form thereof, wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at about 10.5, about 14.4, about 19.3, about 21.7, and about 24.7 degrees 2θ; and
wherein the disease is cancer, age-related macular degeneration, retinopathy, or retinal vein occlusion.
2. The method of claim 1 , wherein the compound of Formula (I), pharmaceutically acceptable salt, or crystalline form is present in a pharmaceutical composition comprising the compound of Formula (I), pharmaceutically acceptable salt, or crystalline form and one or more pharmaceutically acceptable excipients.
3. The method of claim 1 , wherein the disease is cancer.
4. The method of claim 1 , wherein the disease is retinopathy.
5. The method of claim 1 , wherein the disease is age-related macular degeneration (AMD).
6. The method of claim 1 , wherein the retinopathy is diabetic retinopathy.
7. The method of claim 1 , wherein the disease is retinal vein occlusion.
8. The method of claim 1 , wherein the compound is administered topically, by injection, to the eye, orally, or by inhalation.
9. The method of claim 2 wherein the pharmaceutical composition is administered topically, by injection, to the eye, orally, or by inhalation.
10. The method of claim 2 , wherein the pharmaceutical composition is in a container configured to administer eye drops.
11. A method of inhibiting growth factor signaling in a subject in need thereof, comprising administering to a subject a therapeutically effective amount of a compound of Formula (I),
or a pharmaceutically acceptable salt or a crystalline form thereof, wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at about 10.5, about 14.4, about 19.3, about 21.7, and about 24.7 degrees 2θ.
12. The method of claim 11 , wherein the growth factor signaling is associated with a proliferative disease or an ocular disease.
13. The method of claim 12 , wherein the proliferative disease is cancer.
14. The method of claim 12 , wherein the ocular disease is retinopathy, age-related macular degeneration (AMD), corneal neovascularization, an ocular neovascular disease, diabetic macular edema, cystoid macular edema, retinal vein occlusion.
15. The method of claim 11 , wherein the compound is administered topically, by injection, to the eye, orally, or by inhalation.